79 related articles for article (PubMed ID: 20492346)
1. Education and imaging. Hepatobiliary and pancreatic: multiple sexually transmitted infections.
Nakanishi Y; Seno H; Chiba T; Yamashita Y
J Gastroenterol Hepatol; 2010 Apr; 25(4):843. PubMed ID: 20492346
[No Abstract] [Full Text] [Related]
2. [Lamivudine treatment consensus from relative experts].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
[No Abstract] [Full Text] [Related]
3. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
[TBL] [Abstract][Full Text] [Related]
4. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
5. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management.
Locarnini S
J Gastroenterol Hepatol; 2010 Apr; 25(4):649-51. PubMed ID: 20492319
[No Abstract] [Full Text] [Related]
6. Designing clinical development programs for anti-hepatitis B virus drugs.
Brown NA
Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
[No Abstract] [Full Text] [Related]
7. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.
Kumar M; Sarin SK
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):465-95. PubMed ID: 19072396
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains.
Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Yoshioka K; Yano M; Toyoda H; Kumada T; Goto H
J Gastroenterol Hepatol; 2010 Apr; 25(4):745-9. PubMed ID: 20074155
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion.
Pérez-Grande R; Gutiérrez-Zufiaurre N; Muñoz-Criado S; Blázquez de Castro AM; Vázquez López L; González San Martín F; García Rodríguez JA; Muñoz Bellido JL
Diagn Microbiol Infect Dis; 2009 May; 64(1):80-2. PubMed ID: 19304434
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hepatitis B].
Telegdy L
Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
[TBL] [Abstract][Full Text] [Related]
11. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.
Suzuki Y; Kobayashi M; Ikeda K; Suzuki F; Arfase Y; Akuta N; Hosaka T; Saitoh S; Kobayashi M; Someya T; Matsuda M; Sato J; Watabiki S; Miyakawa Y; Kumada H
J Med Virol; 2005 May; 76(1):33-9. PubMed ID: 15779048
[TBL] [Abstract][Full Text] [Related]
12. Trial of lamivudine in hepatitis B surface antigen carriers with persistent hepatitis B core IgM antibody.
Ali HY
Saudi Med J; 2003 Sep; 24(9):996-9. PubMed ID: 12973486
[TBL] [Abstract][Full Text] [Related]
13. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
14. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
Dore GJ; Cooper DA; Barrett C; Goh LE; Thakrar B; Atkins M
J Infect Dis; 1999 Sep; 180(3):607-13. PubMed ID: 10438346
[TBL] [Abstract][Full Text] [Related]
15. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients?
Orlando R; Tosone G; Tiseo D; Piazza M; Portella G; Ciancia R; Martinelli V; Montante B; Rotoli B
Infection; 2006 Oct; 34(5):282-4. PubMed ID: 17033754
[TBL] [Abstract][Full Text] [Related]
16. HBV-related cutaneous periarteritis nodosa in a patient 16 years after renal transplantation: efficacy of lamivudine.
Bedani PL; Bergami M; Cavazzini PL; Strumia R; Morelli MC; Stabellini G; Gilli P
J Nephrol; 2001; 14(5):428-30. PubMed ID: 11730280
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B escape mutant reactivation in a renal transplant patient.
Le Pendeven C; Cuzon G; Fontaine H; Zatla F; Schneider V; Amiel C; Khayat R; Nicolas JC; Soussan P
J Clin Virol; 2007 Sep; 40(1):74-6. PubMed ID: 17652016
[No Abstract] [Full Text] [Related]
18. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.
Sun LJ; Yu JW; Zhao YH; Kang P; Li SC
J Gastroenterol Hepatol; 2010 Mar; 25(3):583-90. PubMed ID: 19968744
[TBL] [Abstract][Full Text] [Related]
19. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium falciparum and hepatitis B virus co-infection--a rare cause of acute hepatitis.
Rai RR; Jain P
J Gastrointestin Liver Dis; 2009 Jun; 18(2):252-3. PubMed ID: 19565063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
